Clearwater and Cain Brothers, a division of Clearwater’s US partner KeyBanc Capital Markets, have advised WEP Group Holdings Limited (WEP Clinical) on its investment from The Jordan Company, L.P. (TJC). TJC made the investment in partnership with WEP Clinical co-founders Jaswinder Khera and Jaswant Khera who will continue to be significant owners in the business while leading the Company through this next phase of growth.
Headquartered in both London, UK, and North Carolina, USA, and with offices in Ireland and Portugal, WEP Clinical is a specialist pharma services company that partners with drug developers to help patients and physicians gain early access to treatments for rare diseases, cancer and other serious or life-threatening illnesses that have no viable treatment options available. The company is a market leader in the design and execution of expanded access and named patient programs, which provide pre-approval access to promising molecules for patients with critical unmet medical needs. Additionally, WEP Clinical offers real-world data collection, market access services, pharmacovigilance services, patient registry, commercialisation services, clinical trial nursing services and comparator sourcing.
The company has distributed drugs in over 90 countries and leverages its expertise in the physical, legal and regulatory aspects of global pharmaceutical product access, distribution and commercialisation across its connected suite of services.
Clearwater worked alongside US partner Cain Brothers, led by Managing Director John Kerins and Vice President Lee Sophocleous.
